Painkiller: Alert on Meftal issued by the government...?
Meftal is a painkiller that is frequently used for rheumatoid arthritis and menstrual cramps. On november 30, the indian Pharmacopoeia Commission (IPC) released a drug safety alert advising consumers and healthcare professionals to closely monitor the possibility of the adverse drug reaction (ADR) associated with Meftal. In its alert, the commission stated that drug responses associated with eosinophilia and systemic symptoms (DRESS) syndrome were found through preliminary investigation of adverse drug reactions from the Pharmacovigilance Programme of india (PvPI) database.
The advisory recommended individuals to report the issue to the PvPI's national coordination center under the commission by completing a form on the PvPI's website, www.ipc.gov.in, or by calling the PvPI Helpline at 1800-180-3024 or using the ADR PvPI Android mobile app. Mefenamic acid, the primary ingredient in Meftal, is a pain reliever that is used to treat period pain as well as discomfort in the muscles and joints. Additionally, it can ease muscle aches, nerve discomfort, and sore throats.
What is syndrome of dress?
The syndrome of drug rash with eosinophilia and systemic symptoms is a severe, long-lasting idiosyncratic medication reaction. Many terms have been used to characterize it, but the most accurate one seems to be drug rash with eosinophilia and systemic symptoms syndrome. A wide range of clinical symptoms are caused by this syndrome, and they appear two to eight weeks after the offending medicine is started. It was linked to medications such as lamotrigine, allopurinol, and abacavir.